Marinus Pharma Q2 EPS $(0.61) Beats $(0.72) Estimate, Sales $6.08M Beat $5.73M Estimate
Portfolio Pulse from Benzinga Newsdesk
Marinus Pharma reported Q2 earnings per share (EPS) of $(0.61), beating the analyst consensus estimate of $(0.72) by 15.28%. This is a 42.45% increase over losses from the same period last year. The company also reported quarterly sales of $6.08 million, beating the analyst consensus estimate of $5.73 million by 6.13%. This is a 239.72% increase over sales from the same period last year.
August 10, 2023 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Marinus Pharma's Q2 earnings and sales beat analyst estimates, showing significant increases over the same period last year.
Marinus Pharma's better-than-expected Q2 earnings and sales, along with significant year-over-year growth, could positively impact investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100